279 related articles for article (PubMed ID: 14966196)
1. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.
Rao GK; Zhang W; Kaminski NE
J Leukoc Biol; 2004 May; 75(5):884-92. PubMed ID: 14966196
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.
Rao GK; Kaminski NE
J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
4. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.
Järbe TU; Liu Q; Makriyannis A
Psychopharmacology (Berl); 2006 Jan; 184(1):36-45. PubMed ID: 16307294
[TBL] [Abstract][Full Text] [Related]
6. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.
Cox ML; Haller VL; Welch SP
Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560
[TBL] [Abstract][Full Text] [Related]
7. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
8. The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.
Newton CA; Lu T; Nazian SJ; Perkins I; Friedman H; Klein TW
J Leukoc Biol; 2004 Oct; 76(4):854-61. PubMed ID: 15258190
[TBL] [Abstract][Full Text] [Related]
9. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid receptors and T helper cells.
Klein TW; Newton C; Larsen K; Chou J; Perkins I; Lu L; Nong L; Friedman H
J Neuroimmunol; 2004 Feb; 147(1-2):91-4. PubMed ID: 14741435
[TBL] [Abstract][Full Text] [Related]
11. Induction of intracellular calcium elevation by Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels.
Rao GK; Kaminski NE
J Leukoc Biol; 2006 Jan; 79(1):202-13. PubMed ID: 16244107
[TBL] [Abstract][Full Text] [Related]
12. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
13. Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.
Chuchawankul S; Shima M; Buckley NE; Hartmann CB; McCoy KL
Int Immunopharmacol; 2004 Feb; 4(2):265-78. PubMed ID: 14996418
[TBL] [Abstract][Full Text] [Related]
14. Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.
Lu T; Newton C; Perkins I; Friedman H; Klein TW
Eur J Pharmacol; 2006 Feb; 532(1-2):170-7. PubMed ID: 16443217
[TBL] [Abstract][Full Text] [Related]
15. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
Darmani NA; Johnson JC
Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
[TBL] [Abstract][Full Text] [Related]
16. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
17. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors.
Eisenstein TK; Meissler JJ; Wilson Q; Gaughan JP; Adler MW
J Neuroimmunol; 2007 Sep; 189(1-2):17-22. PubMed ID: 17640739
[TBL] [Abstract][Full Text] [Related]
18. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
Anikwue R; Huffman JW; Martin ZL; Welch SP
J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.
DeLong GT; Wolf CE; Poklis A; Lichtman AH
Drug Alcohol Depend; 2010 Nov; 112(1-2):126-33. PubMed ID: 20619971
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.
Raborn ES; Marciano-Cabral F; Buckley NE; Martin BR; Cabral GA
J Neuroimmune Pharmacol; 2008 Jun; 3(2):117-29. PubMed ID: 18247131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
